First Quadrant’s Supernus Pharmaceuticals SUPN Stock Holding History

First Quadrant’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-39,533	Closed	-$938K	–	680
2019 Q4	$938K	Sell	39,533 -1,203	-3%	-$29.2K	0.08%	236
2019 Q3	$1.12M	Buy	40,736 +40,398	+11,952%	+$1.2M	0.11%	203
2019 Q2	$11K	Sell	338 -6,290	-95%	-$216K	﹤0.01%	688
2019 Q1	$232K	Buy	+6,628	New	+$247K	0.02%	471
2015 Q3	–	Sell	-8,500	Closed	-$144K	–	823
2015 Q2	$144K	Hold	8,500	–	–	﹤0.01%	591
2015 Q1	$103K	Buy	+8,500	New	+$80.3K	﹤0.01%	582

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Quadrant's SUPN Position: Q1 2020 in Review

First Quadrant sold out of Supernus Pharmaceuticals (SUPN) in Q1 2020, closing a stake of 39,533 shares — an estimated $938K sold.

First Quadrant first reported a position in SUPN in Q1 2015 and held it in 6 quarters. The position peaked at $1.12M in Q3 2019. 208 funds tracked by Wall St. Rank hold SUPN as of Q1 2020.

First Quadrant reported no remaining Supernus Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
First Quadrant sold 39,533 Supernus Pharmaceuticals shares in Q1 2020, an estimated $938K.
First Quadrant first reported a position in Supernus Pharmaceuticals in Q1 2015 and held it in 6 quarters.
First Quadrant's Supernus Pharmaceuticals position peaked at $1.12M in Q3 2019.
208 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2020.

Based on First Quadrant's 13F filing for Q1 2020, filed 5 May 2020.